Listed products

Keywords:

Product News Download

Quadrivalent Subunit Influenza Vaccine（0.5ml）

The Quadrivalent Subunit Influenza Vaccine is developed using the company's own patented technology and is in phase III clinical trial. It has the characteristics of high purity and good safety, especially suitable for children. Currently, no such products are available on the market at home and abroad.

Keywords:

Listed products

Latest News

The world's first! The monkeypox mRNA vaccine has obtained dual clinical trial approvals from both China and the United States.

The mRNA technology platform has achieved another milestone, with global innovation efforts accelerating.

Ab&B Bio-Tech Co., Ltd. collaborates with Walvax Biotechnology Co., Ltd. to seamlessly connect the third-generation subunit influenza vaccine and embark on a new journey of going global

Monkeypox mRNA Vaccine Secures FDA Clinical Approval, Trivalent Influenza Virus Subunit Vaccine Wins First Bid in Shanxi

Announcement of Pre increase in Performance for 2025 Released

Ab&B Bio-Tech Co., Ltd. has been included in the Hang Seng Composite Index, and its recognition in the capital market continues to increase

Need more help?

Yither Biotech is striving for and committed to producing innovative and quality vaccines to contribute to the development of China’s biomedical industry and the wellness of Chinese and people around the world.

Online Message

CONTACT

E-Mail:
yue.peng@yitherbiotech.com
Hotline:
+86-021-61639751
Address:
No. 5, Lane 1690, zhangheng Road, Pudong New Area, Shanghai

QUICK LINKS

Home
Product
About us
News
Contact

PRODUCTS

Listed products
Products under development

Business license